Skip to main content
OpenTrials
Completed

NCT Number: NCT02814240

Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging

The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatic Steatosis Digestive System Diseases Fatty Liver Liver Diseases Pituitary Gland Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Dijon Bourgogne

Dijon, 21079, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have provided consent
  • Patients over 18 years
  • Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary.

Exclusion criteria

  • Persons without national health insurance
  • Pacemaker (Contra-Indication for MRI)
  • Alcohol consumption greater than 4 glasses a day
  • Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden
  • Presence of metallic implants (Contra-Indication for MRI)
  • Claustrophobia
  • Adult under guardianship
  • Pregnant or breast-feeding women
  • Patients with a liver disease other than non-alcoholic steatosis

Treatment and study plan

NMR

Other

blood samples

Biological

Fibroscan

Other

Primary outcomes

  1. Measurement of liver fat mass by Magnetic Resonance Imaging (MRI)

    Time frame: Measured at Day 0

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Official study title

Hepatic Steatosis and Pituitary Gland Failure, Evaluation by NMR Imaging

Acronym: SHAH

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Jun 27, 2016
Registry last updated
Feb 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.